Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $0.32 in the prior trading day, IGC Pharma Inc (AMEX: IGC) closed at $0.32, up 0.50%. In other words, the price has increased by $0.50 from its previous closing price. On the day, 0.32 million shares were traded. IGC stock price reached its highest trading level at $0.3387 during the session, while it also had its lowest trading level at $0.3165.
Ratios:
Our goal is to gain a better understanding of IGC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.87 and its Current Ratio is at 1.32. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 29662118 and an Enterprise Value of 28678116. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.72 while its Price-to-Book (P/B) ratio in mrq is 3.63. Its current Enterprise Value per Revenue stands at 25.93 whereas that against EBITDA is -3.812.
Stock Price History:
The Beta on a monthly basis for IGC is 0.27, which has changed by -0.13513511 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is -17.29%, while the 200-Day Moving Average is calculated to be -6.92%.
Shares Statistics:
The stock has traded on average 971.55K shares per day over the past 3-months and 399240 shares per day over the last 10 days, according to various share statistics. A total of 91.96M shares are outstanding, with a floating share count of 71.30M. Insiders hold about 23.22% of the company’s shares, while institutions hold 5.86% stake in the company. Shares short for IGC as of 1763078400 were 244156 with a Short Ratio of 0.25, compared to 1760486400 on 278841. Therefore, it implies a Short% of Shares Outstanding of 244156 and a Short% of Float of 0.34999999.
Earnings Estimates
IGC Pharma Inc (IGC) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.02, with high estimates of -$0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between -$0.08 and -$0.08 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is -$0.09, with 2.0 analysts recommending between -$0.08 and -$0.09.
Revenue Estimates
2 analysts predict $316.5k in revenue for. The current quarter. It ranges from a high estimate of $325k to a low estimate of $308k. As of. The current estimate, IGC Pharma Inc’s year-ago sales were $257kFor the next quarter, 2 analysts are estimating revenue of $373.5k. There is a high estimate of $422k for the next quarter, whereas the lowest estimate is $325k.
A total of 2 analysts have provided revenue estimates for IGC’s current fiscal year. The highest revenue estimate was $1.5M, while the lowest revenue estimate was $1.3M, resulting in an average revenue estimate of $1.4M. In the same quarter a year ago, actual revenue was $1.27MBased on 2 analysts’ estimates, the company’s revenue will be $1.57M in the next fiscal year. The high estimate is $1.65M and the low estimate is $1.5M.
